NASDAQ:NVCRNovocure Stock Price, Forecast & News

Novocure's stock was trading at $67.38 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, NVCR shares have decreased by 5.8% and is now trading at $63.45. View which stocks have been most impacted by Coronavirus.

8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Novocure in the last year. There are currently 1 sell rating, 2 hold ratings and 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Novocure.

Novocure is scheduled to release its next quarterly earnings announcement on Thursday, July 23rd 2020. View our earnings forecast for Novocure.

Novocure Ltd (NASDAQ:NVCR) released its quarterly earnings results on Thursday, April, 30th. The medical equipment provider reported $0.04 earnings per share (EPS) for the quarter, topping the Thomson Reuters' consensus estimate of $0.03 by $0.01. The medical equipment provider earned $101.83 million during the quarter, compared to the consensus estimate of $102.10 million. Novocure had a return on equity of 4.39% and a net margin of 2.34%. The firm's quarterly revenue was up 38.9% on a year-over-year basis. During the same period last year, the business posted ($0.13) EPS. View Novocure's earnings history.

8 equities research analysts have issued 12 month price targets for Novocure's shares. Their forecasts range from $58.00 to $90.00. On average, they anticipate Novocure's share price to reach $79.00 in the next year. This suggests a possible upside of 24.5% from the stock's current price. View analysts' price targets for Novocure.

Press coverage about NVCR stock has been trending extremely negative on Thursday, according to InfoTrie Sentiment Analysis. The research group scores the sentiment of press coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Novocure earned a coverage optimism score of -4.3 on InfoTrie's scale. They also gave headlines about the medical equipment provider a news buzz of 7.0 out of 10, meaning that recent press coverage is likely to have an impact on the stock's share price in the next several days. View the latest news aboutNovocure.

Some companies that are related to Novocure include ResMed (RMD), Teleflex (TFX), Insulet (PODD), ABIOMED (ABMD), Hill-Rom (HRC), Penumbra (PEN), Haemonetics (HAE), Globus Medical (GMED), Tandem Diabetes Care (TNDM), Integra Lifesciences (IART), Nevro (NVRO), ICU Medical (ICUI), Irhythm Technologies (IRTC), NuVasive (NUVA) and Merit Medical Systems (MMSI). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Novocure investors own include Chembio Diagnostics (CEMI), Prospect Capital (PSEC), Calumet Specialty Products Partners, L.P (CLMT), Two Harbors Investment (TWO), Blackrock Capital Investment (BKCC), Viper Energy Partners (VNOM), Summit Midstream Partners (SMLP), NVIDIA (NVDA), Washington Prime Group (WPG) and Roper Technologies (ROP).

Novocure trades on the NASDAQ under the ticker symbol "NVCR."

Novocure's stock is owned by a number of retail and institutional investors. Top institutional shareholders include Baillie Gifford & Co. (7.70%), BlackRock Inc. (5.65%), Capital World Investors (4.91%), Capital International Investors (2.54%), State Street Corp (1.73%) and Morgan Stanley (1.23%). Company insiders that own Novocure stock include Asaf Danziger, Charles G Phillips III, Eilon D Kirson, Ely Benaim, Gabriel Leung, Michael J Ambrogi, Pritesh Shah, Todd Christopher Longsworth, Wilhelmus Cm Groenhuysen, William F Doyle and Yoram Palti. View institutional ownership trends for Novocure.

NVCR stock was sold by a variety of institutional investors in the last quarter, including Baillie Gifford & Co., Invesco Ltd., Two Sigma Advisers LP, TimesSquare Capital Management LLC, Morgan Stanley, Morgan Stanley, Capital World Investors, and Mitsubishi UFJ Trust & Banking Corp. Company insiders that have sold Novocure company stock in the last year include Asaf Danziger, Charles G Phillips III, Ely Benaim, Gabriel Leung, Michael J Ambrogi, Pritesh Shah, Todd Christopher Longsworth, Wilhelmus Cm Groenhuysen, and William F Doyle. View insider buying and selling activity for Novocure.

NVCR stock was acquired by a variety of institutional investors in the last quarter, including Capital International Investors, RA Capital Management L.P., Redwood Investments LLC, Healthcare of Ontario Pension Plan Trust Fund, Fiera Capital Corp, Frontier Capital Management Co. LLC, Phoenix Holdings Ltd., and Wellington Management Group LLP. View insider buying and selling activity for Novocure.

Shares of NVCR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of NVCR stock can currently be purchased for approximately $63.45.

Novocure has a market capitalization of $6.37 billion and generates $351.32 million in revenue each year. The medical equipment provider earns $-7,230,000.00 in net income (profit) each year or ($0.07) on an earnings per share basis.

The official website for Novocure is www.novocure.com.

Novocure's mailing address is NO. 4 THE FORUM GRENVILLE STREET, ST. HELIER Y9, JE2 4UF. The medical equipment provider can be reached via phone at 44-0-15-3475-6700 or via email at [email protected]